.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Novartis
Merck
Federal Trade Commission
Boehringer Ingelheim
Medtronic
Johnson and Johnson
Colorcon
McKesson
Harvard Business School

Generated: September 25, 2017

DrugPatentWatch Database Preview

ZYPREXA Drug Profile

« Back to Dashboard

Which patents cover Zyprexa, and what generic Zyprexa alternatives are available?

Zyprexa is a drug marketed by Lilly and Eli Lilly Co and is included in four NDAs. There are two patents protecting this drug.

This drug has twenty-six patent family members in twenty-three countries.

The generic ingredient in ZYPREXA is olanzapine pamoate. There are thirty-three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the olanzapine pamoate profile page.

Summary for Tradename: ZYPREXA

Patents:1
Applicants:2
NDAs:4
Suppliers / Packagers: see list11
Bulk Api Vendors: see list93
Clinical Trials: see list42
Patent Applications: see list5,600
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ZYPREXA at DailyMed

Pharmacology for Tradename: ZYPREXA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly
ZYPREXA
olanzapine
INJECTABLE;INTRAMUSCULAR021253-001Mar 29, 2004APRXYesYes► Subscribe► Subscribe► Subscribe
Lilly
ZYPREXA ZYDIS
olanzapine
TABLET, ORALLY DISINTEGRATING;ORAL021086-001Apr 6, 2000ABRXYesYes► Subscribe► Subscribe► Subscribe
Lilly
ZYPREXA ZYDIS
olanzapine
TABLET, ORALLY DISINTEGRATING;ORAL021086-004Apr 6, 2000ABRXYesNo► Subscribe► Subscribe► Subscribe
Lilly
ZYPREXA
olanzapine
TABLET;ORAL020592-003Sep 30, 1996ABRXYesNo► Subscribe► Subscribe► Subscribe
Lilly
ZYPREXA
olanzapine
TABLET;ORAL020592-002Sep 30, 1996ABRXYesYes► Subscribe► Subscribe ► Subscribe
Lilly
ZYPREXA
olanzapine
TABLET;ORAL020592-006Sep 9, 1997ABRXYesNo► Subscribe► Subscribe ► Subscribe
Lilly
ZYPREXA ZYDIS
olanzapine
TABLET, ORALLY DISINTEGRATING;ORAL021086-002Apr 6, 2000ABRXYesNo► Subscribe► Subscribe► Subscribe
Lilly
ZYPREXA
olanzapine
TABLET;ORAL020592-004Sep 30, 1996ABRXYesNo► Subscribe► Subscribe ► Subscribe
Lilly
ZYPREXA ZYDIS
olanzapine
TABLET, ORALLY DISINTEGRATING;ORAL021086-002Apr 6, 2000ABRXYesNo► Subscribe► Subscribe ► Subscribe
Eli Lilly Co
ZYPREXA RELPREVV
olanzapine pamoate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022173-003Dec 11, 2009RXYesYes► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ZYPREXA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lilly
ZYPREXA
olanzapine
TABLET;ORAL020592-006Sep 9, 1997► Subscribe► Subscribe
Lilly
ZYPREXA
olanzapine
TABLET;ORAL020592-005Sep 9, 1997► Subscribe► Subscribe
Lilly
ZYPREXA
olanzapine
TABLET;ORAL020592-005Sep 9, 1997► Subscribe► Subscribe
Lilly
ZYPREXA
olanzapine
TABLET;ORAL020592-002Sep 30, 1996► Subscribe► Subscribe
Lilly
ZYPREXA
olanzapine
TABLET;ORAL020592-006Sep 9, 1997► Subscribe► Subscribe
Lilly
ZYPREXA
olanzapine
INJECTABLE;INTRAMUSCULAR021253-001Mar 29, 2004► Subscribe► Subscribe
Lilly
ZYPREXA
olanzapine
TABLET;ORAL020592-002Sep 30, 1996► Subscribe► Subscribe
Lilly
ZYPREXA
olanzapine
TABLET;ORAL020592-001Sep 30, 1996► Subscribe► Subscribe
Lilly
ZYPREXA
olanzapine
TABLET;ORAL020592-005Sep 9, 1997► Subscribe► Subscribe
Lilly
ZYPREXA
olanzapine
TABLET;ORAL020592-004Sep 30, 1996► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ZYPREXA

Country Document Number Estimated Expiration
Brazil9911049► Subscribe
Australia4008699► Subscribe
Slovakia17512000► Subscribe
World Intellectual Property Organization (WIPO)9961027► Subscribe
Ukraine78181► Subscribe
Norway20005885► Subscribe
Indonesia26861► Subscribe
TaiwanI226829► Subscribe
Czech Republic20004279► Subscribe
South Africa200006815► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ZYPREXA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB96/058United Kingdom► SubscribePRODUCT NAME: OLANZAPINE OPTIONALLY IN THE FORM OF AN ACID ADDITION SALT; REGISTERED: UK EU/1/96/022/001 19960927; UK EU/1/96/022/002 19960927; UK EU/1/96/022/003 19960927; UK EU/1/96/022/004 19960927; UK EU/1/96/022/005 19960927; UK EU/1/96/022/006 19960927; UK EU/1/96/022/007 19960927; UK EU/1/96/022/008 19960927; UK EU/1/96/022/009 19960927; UK EU/1/96/022/010 19960927
70015Netherlands► SubscribePRODUCT NAME: OLANZAPINE, DESGEWENST IN DE VORM VAN EEN ZUURADDITIEZOUT; REGISTRATION NO/DATE: EU/1/96/022/001 - EU/1/96/022/010 19960927
C0012Belgium► SubscribePRODUCT NAME: OLANZAPINE; REGISTRATION NO/DATE: EU/1/96/022/001 19960927
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

UBS
Cerilliant
Cantor Fitzgerald
Chinese Patent Office
Fuji
Queensland Health
Dow
Express Scripts
Citi
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot